Hubris Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.40 M
- Company Age 17 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.74 M
- Revenue Growth 2.02%
- Profit Growth 10.62%
- Ebitda -40.12%
- Net Worth 8.77%
- Total Assets 138.32%
About Hubris Pharmaceuticals
Hubris Pharmaceuticals Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 September 2007 and has a history of 17 years and five months. Its registered office is in Coimbatore, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹1.74 M.
Zakir Parveen and Nisar Hussain serve as directors at the Company.
Company Details
- Location
Coimbatore, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230TZ2007PTC013932
- Company No.
013932
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Sep 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
What products or services does Hubris Pharmaceuticals Private Limited offer?
Hubris Pharmaceuticals Private Limited offers a wide range of products and services, including Packaging Boxes, Cardboard Packaging Box.
Who are the key members and board of directors at Hubris Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nisar Hussain  | Managing Director | 14-Sep-2007 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Zakir Parveen | Director | 14-Sep-2007 | Current |
Financial Performance of Hubris Pharmaceuticals.
Hubris Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 2.02% increase. The company also saw a substantial improvement in profitability, with a 10.62% increase in profit. The company's net worth moved up by a moderate rise of 8.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hubris Pharmaceuticals?
In 2019, Hubris Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.74 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.17 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Nov 2019 | Others | ₹1.74 M | Open |
How Many Employees Work at Hubris Pharmaceuticals?
Unlock and access historical data on people associated with Hubris Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hubris Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hubris Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
